Takeda計(jì)劃開(kāi)發(fā)norovirus疫苗

Takeda公司宣布公司計(jì)劃開(kāi)發(fā)針對(duì)norovirus病毒的疫苗。據(jù)估計(jì)美國(guó)每年有2100萬(wàn)人被該病毒所感染，大概800人每年死于這種病毒引發(fā)的疾病。此次Takeda公司研制的norovirus疫苗融合了兩種亞型的norovirus病毒，因而能夠有效保護(hù)接種者不受環(huán)境中不同病毒亞型的影響。其市場(chǎng)估計(jì)每年可達(dá)四億美元。（生物谷Bioon.com）

詳細(xì)英文報(bào)道：

Bloomberg has an extensive article today on Takeda's leading effort to develop a norovirus--or vomiting bug--vaccine that could prove a boon to the cruise ships and schools which are often afflicted with outbreaks. Every year about 21 million people in the U.S. are infected, and about 800 die. This experimental vaccine combines components of two types of norovirus, which Takeda believes should provide an effective guard against all the viral strains in circulation. And some analysts believe it could be worth up to $400 million a year in revenue if Takeda can get an approval ahead of its rivals.http://www.xiyam.com/